Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) – Beigene

⟵ Back to Search Results

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Beigene Study ID

BGB-A317-315

ClinicalTrials.gov ID

NCT04379635

China Drug Trials ID

CTR20200821

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents